Single-center study: The diagnostic performance of contrast-enhanced ultrasound (CEUS) for assessing focal splenic lesions compared to CT and MRI

2019 ◽  
Vol 73 (1) ◽  
pp. 65-71 ◽  
Author(s):  
V. Schwarze ◽  
F. Lindner ◽  
C. Marschner ◽  
G. Negrão de Figueiredo ◽  
J. Rübenthaler ◽  
...  
2020 ◽  
Vol 54 (2) ◽  
pp. 135-140 ◽  
Author(s):  
Vincent Schwarze ◽  
Constantin Marschner ◽  
Giovanna Negrão de Figueiredo ◽  
Thomas Knösel ◽  
Johannes Rübenthaler ◽  
...  

2020 ◽  
Vol 46 (2) ◽  
pp. e5
Author(s):  
Hendrien Kuipers ◽  
Frederik Hoogwater ◽  
Jules Slangen ◽  
Marieke de Boer ◽  
Robbert de Haas

2020 ◽  
Vol 10 (9) ◽  
pp. 1739-1747
Author(s):  
Vincent Schwarze ◽  
Constantin Marschner ◽  
Giovanna Negrao De Figueiredo ◽  
Michael Ingrisch ◽  
Johannes Rübenthaler ◽  
...  

Radiology ◽  
2010 ◽  
Vol 255 (3) ◽  
pp. 764-771 ◽  
Author(s):  
Shaun Loh ◽  
Sepideh Bagheri ◽  
Richard W. Katzberg ◽  
Maxwell A. Fung ◽  
Chin-Shang Li

2019 ◽  
Vol 8 (9) ◽  
pp. 1353 ◽  
Author(s):  
Hsiao ◽  
Chen ◽  
Huang

Aim: This prospective study assessed the diagnostic value of contrast-enhanced ultrasound (CEUS) using long Kupffer phase enhancement for adults with liver tumor size of less than 3 cm. Performance comparisons were also conducted with dynamic computed tomography (CT) and magnetic resonance imaging (MRI). Background: CEUS has emerged as a reliable image modality, since the development of second-generation contrast medium with long Kupffer phase enhancement. Nonetheless, dynamic CT and MRI are currently the standard imaging tools for the diagnosis of liver cancers, and the diagnostic value of CEUS for liver cancer has yet to be universally accepted. Methods: Sixty-six adult patients suspected of having liver tumors smaller than 3 cm underwent CEUS, dynamic CT, and MRI examinations independently. Subsequent tumor biopsies were used to verify the diagnostic performance of the three imaging modalities. Results: The diagnostic odds ratio (DOR, 95% CI) for hepatocellular carcinoma were as follows: CEUS (52.8, 11.4–243), CT (29.29, 7.36–116), and MRI (19.43, 5.44–69.4); for metastasis: CEUS (200, 19.1–2095), CT (24, 5.05–114), and MRI (32, 6.56–156); and all liver malignancy: CEUS (260, 12.7–5310), CT (2.57, 0.55–12.1), and MRI (5.22, 1.25–21.8). CEUS achieved the best differentiation performance. Conclusions: CEUS outperformed dynamic CT and MRI in terms of diagnostic performance when dealing with small liver tumors (<3 cm).


2019 ◽  
Vol 73 (2) ◽  
pp. 347-357 ◽  
Author(s):  
Markus Herbert Lerchbaumer ◽  
Timo Alexander Auer ◽  
Garcia Stephan Marticorena ◽  
Carsten Stephan ◽  
Bernd Hamm ◽  
...  

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 798-798
Author(s):  
Dominique Bechade ◽  
Carine A. Bellera ◽  
Coralie Cantarel ◽  
Isabelle Soubeyran ◽  
Marc Debled ◽  
...  

798 Background: In the context of a new cancer or relapse, the high sensitivity (Se) (95-100%) of PET-CT with 18F-FDG can lead to the demonstration of hypermetabolic mediastinal adenopathies. Its lower specificity (Sp) (89%) can require histological examination. We report the results of a prospective, single-center study evaluating the diagnostic performance of EUS-FNA in this indication. Methods: Prospective single-center study featuring patients in whom PET had revealed hypermetabolic mediastinal lymphadenopathy requiring diagnostic certainty. All EUS-FNA were performed with a 19-gauge needle (EchoTip, Cook Endoscopy). Main objective: To evaluate the diagnostic performance in terms of Se and Sp of EUS-FNA in the characterization of hypermetabolic mediastinal adenopathies in PET in the context of a new cancer or relapse. Secondary objectives: To evaluate the negative predictive value (NPV) of the EUS-FNA and to evaluate the percentage of surgical diagnostic procedures avoided. The standard technique was a thoraco-abdominopelvic CT scan at 6 months and at 12 months. Results: 52 patients were eligible and evaluable for the primary endpoint. The most common primary cancers were mammary (17.3%) and bronchial (13.5%). The lymph nodes were analyzed as malignant in 44.2% of cases, benign in 50% of cases and atypical or suspicious in 3.8% of cases. The malignant lymph nodes were metastatic for breast cancer in 21.7% of cases, bronchial cancer in 17.4% of cases, colorectal cancer in 17.4% of cases and prostate cancer in 13% of cases. The Se of the EUS-FNA was 92% (95% CI 0.74-0.99) and the Sp 100%. NPV was 87% (95% CI: 0.59-0.98). A diagnostic surgical procedure was necessary in 2% of the cases. PET and EUS-FNA often allowed the modification of the therapeutic strategy. Conclusions: When a confirmed diagnosis is required, the diagnostic accuracy of the minimally invasive procedure of EUS-FNA, is sufficiently robust to avoid a surgical diagnosis technique. The combination of PET and EUS-FNA may alter the therapeutic strategy that would have been considered after PET alone. Clinical trial information: NCT01892501.


2019 ◽  
Vol 41 (01) ◽  
pp. 29-35 ◽  
Author(s):  
Vincent Schwarze ◽  
Constantin Marschner ◽  
Giovanna Negrão de Figueiredo ◽  
Johannes Rübenthaler ◽  
Dirk-André Clevert

Abstract Background Ultrasound is an essential imaging tool for evaluating physiological and pathological fetal or maternal conditions during pregnancy. Published data is limited with respect to the application of CEUS during pregnancy. CEUS has already been safely applied for assessing uteroplacental blood flow, cesarean scar pregnancy and invasive placenta percreta. CT and MRI scans during pregnancy must be thoroughly evaluated due to harmful ionizing radiation and cerebral gadolinium deposition, respectively. Purpose The aim of the present retrospective single-center study is to assess the diagnostic performance and safety of CEUS during pregnancy to evaluate hepatic lesions of unknown entity. Methods 6 pregnant patients who underwent CEUS between 2005 and 2014 (mean age: 32 years; mean weeks of pregnancy: 28 weeks) were included in this study. The applied contrast agent was a second-generation blood-pool agent (SonoVue®, Bracco, Milan, Italy). CEUS examinations were performed and interpreted by a single radiologist with experience since 2000 (EFSUMB Level 3). Results CEUS was safely performed on all included pregnant women without the occurrence of adverse fetal or maternal events. In the context of the present study, CEUS helped to safely differentiate hepatic metastases, focal nodular hyperplasia, atypical hemangioma, hepatic arteriovenous malformation and cystic echinococcosis. In two patients CEUS determined immediate therapy. Conclusion Although not clinically approved in obstetrics so far, CEUS is a safe imaging modality which, in addition to B-mode and color Doppler ultrasonography, may be applied during pregnancy for further medical indications and to provide helpful information.


Sign in / Sign up

Export Citation Format

Share Document